Business Development Partnerships

We are actively seeking strategic partners that align with our vision. We are interested in partnering worldwide rights to the following pre-commercial and commercial assets: 

1.  A-101 45% Topical Solution, our investigational drug candidate for common warts;

2. ATI-501 oral and ATI-502 topical Janus Kinase (JAK) 1/3 inhibitors, our investigational drug candidates for the potential treatment of alopecia; and 

3. ESKATA® (hydrogen peroxide) topical solution, 40% (w/w), our FDA-approved product for the treatment of seborrheic keratoses that are raised.  

Learn more about ESKATA®

Prescribing Information »


We are actively seeking research and licensing partners to fully leverage the transformational potential of our KINect™ platform for drug discovery. Specific areas of interest include:

  • Kinases inhibitors for autoimmune diseases, such as rheumatoid arthritis, chronic inflammation disease (e.g. inflammatory bowel disease), autoinflammatory diseases (e.g. CAPS, Stills Disease), and cancer. 
  • New therapeutic applications for our cysteinome-targeted chemical library representing 60% of the kinome.

Learn more about the KINectTM platform

If you are interested in participating in an investigator-initiated study, find out more.